NCBiotech News

 

Chaseman Global, an international life sciences executive recruitment company, opened a regional office today at the North Carolina Biotechnology Center’s Landing Pad rental office site.

RTP-based AskBio has signed a multi-year research collaboration and option agreement with Bay-area firm ReCode Therapeutics to develop gene-editing technology for driving new precision therapies.

Datar Cancer Genetics, a global company developing blood-based diagnostics for cancer, with a U.S. base in Morrisville, has received the FDA’s breakthrough devices designation for its non-invasive test to help diagnose brain tumors.

Life sciences and related companies from around the world announced new or expanded facilities in 2022 that will bring more than $2.1 billion in investment and over 2,700 new jobs to North Carolina.

Mazen Animal Health, an Iowa startup company that’s developing corn-based oral vaccines for animals, has selected the Research Triangle Park as the home for its research and development center.

Polarean Imaging, a Durham medical imaging technology company, has received FDA clearance for a drug and device combination product that helps doctors visualize lung function in patients with chronic lung disease

RTP gene therapy startup Opus Genetics has acquired the rights to two pre-clinical product candidates to treat inherited retinal diseases from New Jersey biopharm company Iveric Bio.

Durham's Altis Biosystems is granting Plakous Therapeutics up to $10K to support development of the Winston-Salem company's drug to treat necrotizing enterocolitis.

Greensboro-based Kepley Biosystems has netted a $1M NSF grant to support its work growing horseshoe crabs and using their blue blood for diagnostic purposes.

A little bit of Sweden has migrated to North Carolina with the opening of TFS HealthScience’s U.S. headquarters in Durham.

Catalent, a major CDMO with two key facilities in North Carolina, says will invest up to $40 million to add a third -- a Durham County campus that will create 201 jobs upon completion.

Lusaris Therapeutics has announced plans to set up shop in RTP with $60 million in hand to develop its naturally derived and fast-acting psychedelic compound for treatment-resistant depression and other debilitating neuropsychiatric disorders.

The European Society of Gene and Cell Therapy has recognized North Carolina gene therapy pioneer and entrepreneur Jude Samulski, Ph.D., with its inaugural Founders Award.

The newly published analysis "Evidence & Opportunity 2022: Impact of Life Sciences in NC" documents why North Carolina continues to garner global admiration in the field.